Supportive Care

Axel Grothey, MD, from the Mayo Clinic, Rochester, Minnesota, discusses the time course of adverse events following treatment with regorafenib, as observed in the CORRECT study.

ASCO issues recommendations for improving cancer survivorship care.

Patients considering chemotherapy treatment need to understand the risks and benefits of treatment in order to make an informed decision to undergo-or forgo-treatment.

Cancer impacts the lives of patients in many different ways, but one way in which adults facing a cancer diagnosis may be affected is the impact that the disease and its subsequent treatment can have on sexual function.

Pain is as prevalent in ambulatory oncology patients with common solid tumors as it was nearly two decades ago despite the dramatic increase in opioid prescriptions.

Enzalutamide significantly delayed the time to first SRE and significantly improved pain and QOL compared with placebo in men with mCRPC who had received prior docetaxel.

The last year of life is associated with high health expenditures in the United States, and the costs are increasingly focused on patients' last few months.

Patients receiving a daily regimen of L-carnitine did not experience improved fatigue versus placebo on the widely validated Brief Fatigue Inventory.

As an increasing number of cancers are considered chronic diseases treatable with continuous drug delivery, it is essential that our vocabulary describing the side effects experienced by our patients more appropriately reflects this new paradigm.

Michael L. Krychman, MD, Executive Director of the Southern California Center for Sexual Health and Survivorship Medicine, discusses managing and treating sexual health concerns in cancer patients and survivors.

Karen Masino, from Ingalls Memorial Hospital, discusses the intricacies of developing a survivorship program.

Rajni Kannan discusses the importance patient education or managing the side effects associated ipilimumab and vemurafenib in metastatic melanoma.

The addition of aprepitant to standard antiemetic prophylaxis significantly improved the complete response rate in patients with germ cell tumors undergoing 5-day cisplatin combination chemotherapy regimens.

Facilities seeking Commission on Cancer accreditation now need to have a patient navigation process in place by 2015.

Kathleen M. Foley, MD, from Memorial Sloan-Kettering Cancer Center, on the history and future goals for cancer pain management.

Cancer and its treatment creates or aggravates psychosocial distress, while unresolved physical and practical problems can also add to the distress of patients attempting to complete their treatment and recovery.

Whether brought about by surgery or medical treatments, induced menopause forces women to deal with a number of emotional, physical, and practical issues-all in addition to the original diagnosis.

Carrie Stricker from the Abramson Cancer Center of the University of Pennsylvania on the Efficacy of Survivorship Care Plans for Posttreatment Breast Cancer Survivors.

New data show that cancer-related fatigue is reported by only "a small minority" of women >6 months after completing adjuvant therapy for breast cancer.

Anemia is common and associated with functional disability in patients with cancer aged ≥65 years, according to the results of a study presented at ASCO 2012.

Donna Berry, from the Dana-Farber Cancer Institute, Explains a Nurse-Led Education Program That Enhanced Oral Therapy Compliance.

Forty years after the declaration of war on cancer, one of the most profound shifts in cancer care today is a new focus on treating those living beyond cancer, as well as those living with cancer.

Two medications that are not recommended in guidelines for the standard treatment of cancer-related febrile neutropenia are commonly used- particularly outside of high-volume medical settings- yet are not effective.

A new paradigm that relies on identifying networks or clusters of single nucleotide polymorphisms can accurately predict which patients will develop treatment-related mucositis and other side effects.

Research is needed to justify the dollar savings achieved by a supportive care program, but it is not clear what should be measured and how studies should be designed to demonstrate this.